Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA.
Emerg Infect Dis
; 29(11): 2353-2357, 2023 11.
Article
en En
| MEDLINE
| ID: mdl-37796277
We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other). Future public health emergency responses must prioritize institutional and structural racism mitigation.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Mpox
Aspecto:
Determinantes_sociais_saude
/
Equity_inequality
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Emerg Infect Dis
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2023
Tipo del documento:
Article
Pais de publicación:
Estados Unidos